Drug repositioning: a brief overview

Pushpakom, 2019, Drug repurposing: progress, challenges and recommendations, Nat Rev Drug Discov, 18, 41, 10.1038/nrd.2018.168

Ashburn, 2004, Drug repositioning: identifying and developing new uses for existing drugs, Nat Rev Drug Discov, 3, 673, 10.1038/nrd1468

Langedijk, 2015, Drug repositioning and repurposing: terminology and definitions in literature, Drug Discov Today, 20, 1027, 10.1016/j.drudis.2015.05.001

Wermuth, 2006, Selective optimization of side activities: the SOSA approach, Drug Discov Today, 11, 160, 10.1016/S1359-6446(05)03686-X

March-Vila, 2017, On the integration of in silico drug design methods for drug repurposing, Front Pharmacol, 8, 298, 10.3389/fphar.2017.00298

Iwata, 2015, Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic and molecular data, J Chem Inf Model, 55, 446, 10.1021/ci500670q

Dovrolis, 2017, Laying in silico pipelines for drug repositioning: a paradigm in ensemble analysis for neurodegenerative diseases, Drug Discov Today, 22, 805, 10.1016/j.drudis.2017.03.009

Nosengo, 2016, Can you teach old drugs new tricks?, Nature, 534, 314, 10.1038/534314a

Naylor, 2014, Therapeutic drug repurposing: repositioning and rescue, Drug Discov World, 50

Thayer, Drug Repurposing|October 1, 2012 Issue – Vol. 90 Issue 40|Chemical & Engineering News

Cavalla, 2017, Scientific commercial value of drug repurposing, 3

Rastegar-Mojarad, 2015, Opportunities for drug repositioning from phenome-wide association studies, Nat Biotechnol, 33, 342, 10.1038/nbt.3183

Xu, 2011, Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases, Brief Bioinform, 12, 341, 10.1093/bib/bbr006

Monneret, 2009, Fabuleux hasards: histoire de la découverte de médicaments

Vane, 1971, Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs, Nat New Biol, 231, 232, 10.1038/newbio231232a0

Rothwell, 2011, Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials, Lancet, 377, 31, 10.1016/S0140-6736(10)62110-1

Rüschoff, 1998, Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection, Proc Natl Acad Sci USA, 95, 11301, 10.1073/pnas.95.19.11301

Raje, 1999, Thalidomide – a revival story, N Engl J Med, 341, 1606, 10.1056/NEJM199911183412110

Cummings, 2017, Alzheimer’s disease drug development pipeline: 2017, Alzheimer’s Dement Transl Res Clin Interv, 3, 367, 10.1016/j.trci.2017.05.002

Raoult, 2020, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, Int J Antimicrob Agents

Zhang, 2016, Drug repositioning for Alzheimer’s disease based on systematic “omics” data mining, PLoS ONE, 11, 10.1371/journal.pone.0168812

Brown, 2017, A standard database for drug repositioning, Sci Data, 4, 10.1038/sdata.2017.29

Scannell, 2012, Diagnosing the decline in pharmaceutical R&D efficiency, Nat Rev Drug Discov, 11, 191, 10.1038/nrd3681